Exchange: NASDAQ·Updated 07:30 PM EST

SUPN News

News
all
press releases
Wells Fargo & Company Begins Coverage on Supernus Pharmaceuticals (NASDAQ:SUPN)
Wells Fargo & Company started coverage on shares of Supernus Pharmaceuticals in a research note on Friday. They issued an "overweight" rating and a $54.00 price objective on the stock...
MarketBeat
Wells Fargo & Company Begins Coverage on Supernus Pharmaceuticals (NASDAQ:SUPN)
Wells Fargo & Company started coverage on shares of Supernus Pharmaceuticals in a research note on Friday. They issued an "overweight" rating and a $54.00 price objective on the stock...
MarketBeat
More News
Key PointsThe peer is Supernus Pharmaceuticals...
Nasdaq News: Markets
Supernus (SUPN) delivered earnings and revenue surprises of +89.80% and +1.39%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Supernus Pharmaceuticals (NASDAQ:SUPN) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you byread more...
Benzinga
Biogen's Q3 earnings and revenues beat estimates as growth drugs drive sales, while the company tightens its 2026 adjusted EPS outlook amid rising costs.
Zacks
Biogen heads into Q3 earnings with growth from new drugs and acquisitions potentially offsetting declining multiple sclerosis sales.
Zacks
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.
Zacks
Are ITGR, BZH, SUPN Obtaining Fair Deals for their Shareholders? Are ITGR, BZH, SUPN Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 25, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...
PR Newswire
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) to Indivior Pharmaceuticals, Inc. for 1.5401 common shares of Indivior for each share of Supernus.Halper Sadeh encourages Supernus shareholders to click here to learn more about...
Business Wire

Advertisement|Remove ads.